Sciomics

Protein profiling plays a crucial role in the advancement of biomedical research, enabling us to improve patients quality of life by utilizing molecular signatures for accurate diagnosis and treatment. At Sciomics, our passion for advanced protein profiling is driving the future of Precision Medicine. We are continually expanding our biomarker signature pipeline to address a wide range of clinical indications and to advance Precision Diagnostics. Our cutting-edge services enable scientists worldwide to unravel the complexities of disease, uncover modes of action and identify promising protein biomarker candidates. Our service portfolio is anchored in our state-of-the-art scioDiscover microarray platform for protein...

Antibody microarrays,proteomics,biomarker,highly parallel protein analysis,precision medicine,diagnostics,acute kidney injury,bladder cancer,pancreatic cancer,oncological biomarkers,companion diagnostics,personalised medicine,phosphoproteomics,phosphorylation analysis,posttranslational modifications,and ubiquitination

Sciomics operates in the Biotechnology industry.

Sciomics's revenue is 1m - 10m

Sciomics has 11 - 50 employees.